Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dextroamphetamine
Drug ID BADD_D00636
Description Dextroamphetamine is the dextrorotary enantiomer of amphetamine[A2505]. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label].
Indications and Usage Dextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).[Label]
Marketing Status approved; illicit
ATC Code N06BA02
DrugBank ID DB01576
KEGG ID D03740
MeSH ID D003913
PubChem ID 5826
TTD Drug ID D0T3LF
NDC Product Code 68968-0215; 72162-2043; 68968-0220; 68968-0210; 68968-0205; 27808-085
UNII TZ47U051FI
Synonyms Dextroamphetamine | Dexamphetamine | Dexamfetamine | dextro-Amphetamine | dextro Amphetamine | d-Amphetamine | d Amphetamine | Dexedrine | DextroStat | Oxydess | Curban | Dextroamphetamine Sulfate | Sulfate, Dextroamphetamine | Dextro-Amphetamine Sulfate | Dextro Amphetamine Sulfate | d-Amphetamine Sulfate | d Amphetamine Sulfate
Chemical Information
Molecular Formula C9H13N
CAS Registry Number 51-64-9
SMILES CC(CC1=CC=CC=C1)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Intentional self-injury12.01.08.036; 19.12.01.002---
Irritability08.01.03.011; 19.04.02.013--
Lacrimation increased06.08.02.004--
Lethargy08.01.01.008; 17.02.04.003; 19.04.04.0040.001530%
Livedo reticularis23.06.05.001; 24.03.04.003---
Malaise08.01.01.003--
Memory impairment17.03.02.003; 19.20.01.003--
Mental impairment17.03.03.002; 19.21.02.003---
Migraine17.14.02.001; 24.03.05.003---
Mood altered19.04.02.007---
Mood swings19.04.03.001---
Mydriasis06.05.03.004; 17.02.11.003---
Nausea07.01.07.0010.003286%
Pallor08.01.03.032; 23.03.03.031; 24.03.04.001---
Palpitations02.11.04.012--
Paraesthesia17.02.06.005; 23.03.03.0940.000990%
Paranoia19.05.01.005---
Peripheral coldness08.01.09.010; 23.06.04.008; 24.04.03.006---
Personality change17.02.05.019; 19.05.01.006--
Personality disorder19.05.02.002---
Psychomotor hyperactivity17.01.02.011; 19.11.02.003---
Rash pruritic23.03.13.030---
Restlessness17.02.05.021; 19.11.02.002--
Rhabdomyolysis15.05.05.0020.000675%
Seizure17.12.03.001--
Skin discolouration23.03.03.005---
Sleep disorder19.02.04.001---
Social avoidant behaviour19.05.01.007---
Somnolence17.02.04.006; 19.02.05.0030.003286%
Speech disorder17.02.08.003; 19.19.02.002; 22.12.03.027---
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages